WINTON GROUP Ltd Boosts Holdings in Zynex, Inc. (NASDAQ:ZYXI)

WINTON GROUP Ltd boosted its position in shares of Zynex, Inc. (NASDAQ:ZYXI) by 147.6% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,841 shares of the company’s stock after buying an additional 21,960 shares during the quarter. WINTON GROUP Ltd owned 0.12% of Zynex worth $343,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. State Board of Administration of Florida Retirement System purchased a new position in Zynex during the first quarter worth $137,000. Quest Partners LLC boosted its stake in Zynex by 646.7% during the second quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock worth $120,000 after buying an additional 11,195 shares during the period. Principal Financial Group Inc. boosted its stake in Zynex by 56.4% during the first quarter. Principal Financial Group Inc. now owns 17,679 shares of the company’s stock worth $219,000 after buying an additional 6,378 shares during the period. BOKF NA purchased a new position in Zynex during the first quarter worth $246,000. Finally, Platte River Wealth Advisors LLC boosted its stake in Zynex by 200.0% during the second quarter. Platte River Wealth Advisors LLC now owns 30,000 shares of the company’s stock worth $280,000 after buying an additional 20,000 shares during the period. 29.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on ZYXI shares. Royal Bank of Canada dropped their price objective on shares of Zynex from $15.00 to $12.00 and set an “outperform” rating for the company in a research note on Friday, July 26th. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Zynex in a research note on Wednesday, September 4th.

Zynex Stock Down 0.1 %

Shares of ZYXI opened at $8.18 on Thursday. The firm has a market capitalization of $259.63 million, a P/E ratio of 35.57 and a beta of 0.54. Zynex, Inc. has a 12-month low of $7.04 and a 12-month high of $13.77. The company has a current ratio of 4.06, a quick ratio of 3.22 and a debt-to-equity ratio of 1.79. The firm has a fifty day moving average price of $8.40 and a 200-day moving average price of $10.03.

Zynex (NASDAQ:ZYXI) last issued its earnings results on Thursday, July 25th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). The company had revenue of $49.88 million for the quarter, compared to analysts’ expectations of $51.99 million. Zynex had a net margin of 3.12% and a return on equity of 14.15%. The firm’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.09 earnings per share. Equities research analysts expect that Zynex, Inc. will post 0.22 earnings per share for the current year.

Insider Activity at Zynex

In related news, COO Anna Lucsok sold 8,083 shares of Zynex stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $8.03, for a total value of $64,906.49. Following the completion of the sale, the chief operating officer now directly owns 16,980 shares in the company, valued at $136,349.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, COO Anna Lucsok sold 8,083 shares of Zynex stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $8.03, for a total value of $64,906.49. Following the completion of the sale, the chief operating officer now directly owns 16,980 shares in the company, valued at $136,349.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joshua R. Disbrow acquired 7,000 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The stock was purchased at an average price of $8.32 per share, with a total value of $58,240.00. Following the completion of the acquisition, the director now directly owns 72,000 shares of the company’s stock, valued at $599,040. The disclosure for this purchase can be found here. 52.13% of the stock is currently owned by corporate insiders.

Zynex Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.